Register Login
Register to leave comments
  • News bot May 8, 2026, 12:46 p.m.

    📋 MOLECULIN BIOTECH, INC. (MBRX) - Clinical Trial Update

    Filing Date: 2026-05-08

    Accepted: 2026-05-08 08:45:12

    Event Type: Clinical Trial Update

    Event Details:

    MOLECULIN BIOTECH, INC. (MBRX) Announces Clinical Trial Update MOLECULIN BIOTECH, INC. (MBRX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: foundation, rights
    • Diseases/Conditions: Hong Kong, Annamycin
    • Clinical Stage: Phase 3
    • Collaboration: The University of Texas System
      • targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122

    🔬 Clinical Development Pipeline (MOLECULIN BIOTECH, INC.):

    Product Type Development Stage Therapeutic Area Source
    Cytarabine Other Phase PHASE1 Leukemia, Myeloid, Acute ClinicalTrials.gov
    WP1122 Other Phase PHASE1 Healthy Volunteer ClinicalTrials.gov
    Placebo Other Phase PHASE2 Psoriasis ClinicalTrials.gov
    MOL4239 Other Phase PHASE2 Psoriasis ClinicalTrials.gov
    WP1220 Other Phase PHASE1 Cutaneous T-Cell Lymphoma/Mycosis Fungoides ClinicalTrials.gov
    Liposomal Annamycin Other Phase PHASE1 Leukemia, Myeloid, Acute ClinicalTrials.gov
    Liposomal Annamycin (L-Annamycin) Other Phase PHASE1 Sarcoma,Soft Tissue ClinicalTrials.gov
    Surgical Procedure Procedure Phase PHASE2 Glioblastoma, IDH-Wildtype ClinicalTrials.gov
    STAT3 Inhibitor WP1066 Other Phase PHASE2 Glioblastoma, IDH-Wildtype ClinicalTrials.gov
    Radiation Therapy Drug Phase PHASE2 Glioblastoma, IDH-Wildtype ClinicalTrials.gov
    Magnetic Resonance Imaging Other Phase PHASE2 Glioblastoma, IDH-Wildtype ClinicalTrials.gov
    Biospecimen Collection Other Phase PHASE2 Glioblastoma, IDH-Wildtype ClinicalTrials.gov
    Liposomal Annamycin for Injection in combination with Cytarabine Injection. Other Phase PHASE2 Acute Myeloid Leukaemia (AML) ClinicalTrials.gov
    Liposomal Annamycin Injection in combination with Cytarabine Injection Other Phase PHASE2 Acute Myeloid Leukaemia (AML) ClinicalTrials.gov
    Placebo in combination with Cytarabine Injection Other Phase PHASE2 Acute Myeloid Leukaemia (AML) ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: MOLECULIN BIOTECH, INC.
    • Ticker Symbol: MBRX

Search

News categories